近日，国家医疗保障局通报了一起涉及药品‘万脉宁’的严重回扣案件。经查，某医药企业在销售‘万脉宁’（一种用于治疗静脉疾病的处方药）过程中，通过向医疗机构及医务人员支付高额回扣的方式，诱导医生超量开方、不合理用药，严重扰乱了医保基金使用秩序，并损害患者利益。国家医保局已依法对该企业作出处理，包括暂停其相关药品挂网采购资格、追回违规使用的医保资金，并将线索移交纪检监察和公安部门进一步查处。此案是国家医保局深化医药领域反腐、强化医保基金监管的重要举措之一。近年来，医保部门持续加大对‘带金销售’等违法行为的打击力度，推动建立公平、透明、合规的医药购销环境。此次通报也警示所有医药企业必须严格遵守法律法规，杜绝商业贿赂行为，切实维护医保基金安全和公众健康权益。
Recently, China’s National Healthcare Security Administration (NHSA) disclosed a serious kickback case involving the drug ‘Wanmaining,’ a prescription medication used to treat venous disorders. The investigation revealed that a pharmaceutical company offered substantial kickbacks to medical institutions and healthcare professionals to incentivize excessive and inappropriate prescriptions of the drug. This practice severely disrupted the proper use of medical insurance funds and harmed patient interests. In response, the NHSA has suspended the drug’s eligibility for inclusion in public procurement platforms, recovered misused insurance funds, and referred the case to disciplinary inspection and public security authorities for further legal action. This case underscores the NHSA’s ongoing efforts to combat corruption in the pharmaceutical sector and strengthen oversight of medical insurance funds. In recent years, Chinese regulators have intensified crackdowns on unethical sales practices such as ‘sales with hidden commissions’ to foster a fair, transparent, and compliant pharmaceutical market. The announcement serves as a clear warning to all pharmaceutical companies to strictly adhere to laws and regulations, eliminate commercial bribery, and safeguard both public health and the integrity of the national health insurance system.
原创文章，作者：admin，如若转载，请注明出处：https://ktez.cn/12814.html